The Supreme Court intervened on Monday to suspend an appellate ruling that would have blocked the mailing of mifepristone, the drug used in the majority of abortions in the United States. Justice Samuel Alito issued an administrative stay lasting until May 11, buying time for the full court to consider the legal challenge brought by manufacturers of the pill. The temporary reprieve came four days after a three-judge panel of the conservative Fifth Circuit Court of Appeals sided with Louisiana in its bid to halt telehealth prescriptions and postal delivery of mifepristone, arguing that the Food and Drug Administration had exceeded its authority when it loosened those restrictions under the previous administration.

Medication abortion now accounts for more than half of all terminations in the United States, a share that has grown sharply since the Supreme Court overturned Roe v. Wade in 2022. That decision returned abortion regulation to the states, and about twenty states have since imposed near-total bans. The Fifth Circuit’s order, if allowed to stand, would have had nationwide effect, forcing patients in states where abortion remains legal to travel to a clinic for an in-person consultation before obtaining the pill — a journey that could run to hundreds of miles for those living in states with bans.

Viewed from Washington, the case places the Trump administration in a politically delicate position. The president has sought to avoid the abortion debate ahead of the 2026 midterms, but the litigation forces his government to either defend the FDA’s regulatory decisions or side with the anti-abortion movement pushing for stricter restrictions. Analysts in European capitals note that the dispute represents the next front in America’s post-Roe legal battles, one that could determine whether medication abortion — already the most common method — remains accessible via telemedicine even in states that have codified abortion rights.

The stay is only a pause. The Supreme Court must now decide whether to hear the merits of the case, a process that could take months. If the justices ultimately uphold the Fifth Circuit’s reasoning, the implications would extend well beyond mifepristone, calling into question the FDA’s long-standing authority to regulate drug distribution based on evolving scientific evidence. Pro-choice activists have described the challenge as the gravest threat to abortion care since the fall of Roe, while anti-abortion groups see an opportunity to reverse a regulatory shift they argue was improperly granted. For now, the status quo holds — pills can still be ordered online and delivered by post — but the legal sword hangs by a thread.